Efanesoctocog alfa not checked
Swedish Orphan Biovitrum · BIVV001
FollowEvery change as it happens, and a Monday email
Trials
4 active
6 in total · 6 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.”In the company’s words, NCT06940830 on ClinicalTrials.gov
- Tested for
- Haemophilia A (Moderate or Severe) (2 trials), Hemophilia, Classic, Haemophilia, Hemophilia, Classic Hemophilia, Synovial Hypertrophy, Hemophilia A
- Main trialPhase 4
- “The rationale for conducting this open-label phase 4 study is to assess whether once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) improves the disease course of existing synovial hypertrophy and prevents the risk of joint bleeds in patients with moderate or severe haemophilia A. The use of imaging assessments will allow for objective detection and monitoring of synovial hypertrophy, and thus expand on the previous findings demonstrating positive effects of once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) on joint health.”In the company’s words, NCT06752850 on ClinicalTrials.gov
- Other names
- BIVV001 · Altuvoct · Altuviiio
Other drugs for Haemophilia A (Moderate or Severe)
Coming up2
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 17 Nov 2026 | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | |
| Phase 4Active, not recruiting | Dec 2028 | Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa | |
| Phase 3Active, not recruiting | Mar 2027 | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | |
| Phase 3Completed | 2 Jun 2026 | A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa | |
| Phase 1Completed | 21 May 2026 | Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A | |
| Phase 3Authorised | not given | Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026